Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 9/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canertinib SCHEMBL29368458 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29655741 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2141065 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2052123 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL731396 | 0.99 | EGFR (0.97) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL3585133 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30415948 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL13882947 | 0.93 | EGFR (0.86) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-112955137-B | Combination therapy | 米拉蒂治疗股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4412717-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH PAN ERBB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118369119-A | Combination therapy of KRAS G12D inhibitors and pan ErbB family inhibitors | 米拉蒂治疗股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | JUNO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023059596-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4048273-A1 | NOVEL DRUG COMBINATIONS FOR TREATMENT OF A CARCINOMA | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-08-31 | — | — | EP | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114728000-A | Novel pharmaceutical combination for the treatment of cancer | 荷兰癌症研究所-安东尼·范·雷文虎克医院基金会 | 2022-07-08 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | ITK, PBK, BMX | EGFR 37/4885ERBB2 13/4885ERBB4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.